Home > News > Abraxis BioScience: A SPARC for Explosive Growth?
July 20th, 2006
Abraxis BioScience: A SPARC for Explosive Growth?
Abstract:
Abraxis BioScience, Inc. (ABBI) provides a unique opportunity for investment in a biopharmaceutical company that is revolutionizing cancer therapy with its proprietary nanotechnology platform. Abraxis’ nanoparticle albumin-bound, or nab technology, exploits the natural properties of a human protein, albumin, for drug delivery.
Source:
seekingalpha.com
Bookmark:
| Related News Press |
Investments/IPO's/Splits
180 Degree Capital Corp. to Provide Live Remote Access to Its Annual Meeting of Shareholders on June 12, 2018 June 12th, 2018
Nanometrics Updates Time of Webcast at Stifel 2018 Cross Sector Insight Conference June 12th, 2018
Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences May 31st, 2018
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018
Nanomedicine
Nanobiotix Publishes Positive Phase 2/3 Data For Nanomedicine in Soft Tissue Cancer (Webcast June 22) June 22nd, 2018
Collaboration yields discovery of 12-sided silica cages June 20th, 2018
Profiles
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||